Dutasterid/tamsulozin Stada 0,5 mg/0,4 mg tvrde kapsule
| Name | Dutasterid/tamsulozin Stada 0,5 mg/0,4 mg tvrde kapsule |
|---|---|
| Marketing Authorisation Number | HR-H-531736196 |
| Active Substance | dutasterid tamsulozinklorid |
| Composition | jedna tvrda kapsula sadrži 0,5 mg dutasterida i 0,4 mg tamsulozinklorida (odgovara 0,367 mg tamsulozina) |
| Pharmaceutical Form | kapsula, tvrda |
| Manufacturer | STADA Arzneimittel AG, Bad Vilbel, Njemačka
Laboratorios Leon Farma S.A., Villaquialambre, Leon, Španjolska |
| Marketing Authorisation Holder | Stada d.o.o., Hercegovačka 14, Zagreb, Hrvatska |
| Marketing Authorisation Date | 25.06.2024 |
| MA Period of Validity | unlimited |
| MA Revocation Date | 03.11.2026* |
| Classification Number | UP/I-530-09/23-02/158 |
| Registration Number | 381-12-01/70-24-05 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | Medicinal product on medical prescription for renewable delivery |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | G04CA52 |
| Marketing status | Not marketed |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
*Note
Marketing authorisation has been revoked by request of the marketing authorisation holder. In accordance with Article 113 of Medicinal Products Act, only a medicinal product in respect of which a marketing authorisation has been granted by the Agency for Medicinal Products and Medical Devices or the European Commision, and a medicinal product in respect of which an authorisation for parallel import or parallel distribution has been granted may be placed on the market of the Republic of Croatia. By way of derogation from this provision, a batch of medicinal product may be on the market for no longer than 18 months following the expiry of revocation of the marketing authorisation, unless its shelf life expires first.
Packaging
Direct Healthcare Professional Communication
| Name | Date | Download |
|---|---|---|
| Pismo zdravstvenim radnicima o mjerama za smanjenje rizika od suicidalnih misli povezanih s primjenom lijekova koji sadrže dutasterid i finasterid | 09.09.2025 | Zentiva, Viatris Hrvatska, Krka-farma, Genericon Pharma, Alpha-Medical, Belupo lijekovi i kozmetika, PharmaS, Galenika Adria, Pharmakos Consulting, Alkaloid, PLIVA Hrvatska, MIP Pharma Croatia, Organon Pharma |
